Masimo Corporation (NASDAQ:MASI) is set to announce third quarter earning results on Tuesday 27th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, MASI to report 3Q20 income of $ 0.62 per share.
For the full year, analysts anticipate top line of $ 1091.30 million, while looking forward to income of $ 3.17 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 274.00 million ~ $ 278.00 million
Full Year 2020 topline are forecasted in a range of$ 1,124.00 million ~ $ 1,128.00 million, where as bottomline are predicted in a range of $ 3.56 ~ $ 3.56 per share
Click Here For More Historical Outlooks Of Masimo Corporation
Previous Quarter Performance
Masimo Corporation posted income for the second quarter of $ 0.85 per share, from the revenue of $ 300.95 million. The quarterly earnings improved 11.84 percent compared with the same quarter last year. Street analysts expected Masimo Corporation to report income of $ 0.81 per share on revenue of $ 289.73 million for the second quarter. The bottom line results beat street analysts by $ 0.04 or 4.94 percent, at the same time, top line results outshined analysts by $ 11.22 million or 3.87 percent.
Stock Performance
Shares of Masimo Corporation traded up $ 5.11 or 2.13 percent on Friday, reaching $ 244.77 with volume of 274.60 thousand shares. Masimo Corporation has traded high as $ 245.79 and has cracked $ 240.68 on the downward trend
According to the previous trading day, closing price of $ 244.77, representing a 70.54 % increase from the 52 week low of $ 140.53 and a 7.11 % decrease over the 52 week high of $ 258.00.
The company has a market capital of $ 13.45 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Recent Analyst recommendations
- On 2nd September 2020, initiated by Robert W. Baird at Outperform rating, with $ 260.00 target price.
Conference Call
Masimo Corporation will be hosting a conference call at 4:30 PM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.masimo.com
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index.
